62 related articles for article (PubMed ID: 7555375)
21. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors.
Oldenburg J; Kraggerud SM; Cvancarova M; Lothe RA; Fossa SD
J Clin Oncol; 2007 Feb; 25(6):708-14. PubMed ID: 17228018
[TBL] [Abstract][Full Text] [Related]
22. Does cisplatin stimulate erythropoietin secretion from the peritubular cells of the kidney?
Orhan B; Yalçin S; Evrensel T; Kurt E; Manavoğlu O; Erbaş T
Clin Nephrol; 1998 Sep; 50(3):202-3. PubMed ID: 9776431
[No Abstract] [Full Text] [Related]
23. Perilymphatic application of alpha-melanocyte stimulating hormone ameliorates hearing loss caused by systemic administration of cisplatin.
Wolters FL; Klis SF; Hamers FP; de Groot JC; Smoorenburg GF
Hear Res; 2004 Mar; 189(1-2):31-40. PubMed ID: 14987750
[TBL] [Abstract][Full Text] [Related]
24. The role of antioxidants in protection from ototoxic drugs.
Sergi B; Fetoni AR; Ferraresi A; Troiani D; Azzena GB; Paludetti G; Maurizi M
Acta Otolaryngol Suppl; 2004 May; (552):42-5. PubMed ID: 15219046
[TBL] [Abstract][Full Text] [Related]
25. Bromate-induced ototoxicity.
Campbell KC
Toxicology; 2006 Apr; 221(2-3):205-11. PubMed ID: 16460859
[TBL] [Abstract][Full Text] [Related]
26. Morphometric and tridimensional studies of tubular cystic degeneration in rat kidney following exposure to cisplatin.
Zanen J; Carinci V; Nonclercq D; Toubeau G; Laurent G; Heuson-Stiennon JA
Anal Cell Pathol; 1993 Nov; 5(6):353-66. PubMed ID: 8305331
[TBL] [Abstract][Full Text] [Related]
27. Role of non-selective adenosine receptor blockade and phosphodiesterase inhibition in cisplatin-induced nephrogonadal toxicity in rats.
Saad SY; Najjar TA; Alashari M
Clin Exp Pharmacol Physiol; 2004 Dec; 31(12):862-7. PubMed ID: 15659050
[TBL] [Abstract][Full Text] [Related]
28. Effect of noise conditioning on cisplatin-induced ototoxicity: a pilot study.
Theneshkumar S; Lorito G; Giordano P; Petruccelli J; Martini A; Hatzopoulos S
Med Sci Monit; 2009 Jul; 15(7):BR173-7. PubMed ID: 19564816
[TBL] [Abstract][Full Text] [Related]
29. Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen.
Lynch ED; Gu R; Pierce C; Kil J
Hear Res; 2005 Mar; 201(1-2):81-9. PubMed ID: 15721563
[TBL] [Abstract][Full Text] [Related]
30. Supporting cells as a target of cisplatin-induced inner ear damage: therapeutic implications.
Ramírez-Camacho R; García-Berrocal JR; Buján J; Martín-Marero A; Trinidad A
Laryngoscope; 2004 Mar; 114(3):533-7. PubMed ID: 15091230
[TBL] [Abstract][Full Text] [Related]
31. Future opportunities in preventing cisplatin induced ototoxicity.
van den Berg JH; Beijnen JH; Balm AJ; Schellens JH
Cancer Treat Rev; 2006 Aug; 32(5):390-7. PubMed ID: 16781082
[TBL] [Abstract][Full Text] [Related]
32. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma.
Kushner BH; Budnick A; Kramer K; Modak S; Cheung NK
Cancer; 2006 Jul; 107(2):417-22. PubMed ID: 16779793
[TBL] [Abstract][Full Text] [Related]
33. [Urinary lysozyme, beta-2-microglobulin, and alpha-glucosidase during cisplatin therapy].
Airoldi M; Pecchio F; Albanese F; Mastromatteo V; Gariboldi A; Di Costanzo G; Fazio M
Boll Soc Ital Biol Sper; 1983 Mar; 59(3):392-8. PubMed ID: 9704142
[No Abstract] [Full Text] [Related]
34. Distribution of platinum in blood and perilymph in relation to cisplatin induced ototoxicity in the guinea pig.
Sepmeijer JW; Klis SF
Hear Res; 2009 Jan; 247(1):34-9. PubMed ID: 18955125
[TBL] [Abstract][Full Text] [Related]
35. Prevention of noise- and drug-induced hearing loss with D-methionine.
Campbell KC; Meech RP; Klemens JJ; Gerberi MT; Dyrstad SS; Larsen DL; Mitchell DL; El-Azizi M; Verhulst SJ; Hughes LF
Hear Res; 2007 Apr; 226(1-2):92-103. PubMed ID: 17224251
[TBL] [Abstract][Full Text] [Related]
36. Effect of cisplatin on plasma renin activity and serum aldosterone levels.
Kurt E; Manavoglu O; Dilek K; Orhan B; Evrensel T
Clin Nephrol; 1999 Dec; 52(6):397-8. PubMed ID: 10604651
[No Abstract] [Full Text] [Related]
37. Plasmapheresis reverses all side-effects of a cisplatin overdose--a case report and treatment recommendation.
Hofmann G; Bauernhofer T; Krippl P; Lang-Loidolt D; Horn S; Goessler W; Schippinger W; Ploner F; Stoeger H; Samonigg H
BMC Cancer; 2006 Jan; 6():1. PubMed ID: 16390557
[TBL] [Abstract][Full Text] [Related]
38. [Acute tubular necrosis with acute renal failure during the first month of treatment with 5-amino-salicylate (Pentasa(R))].
Beaulieu S; Rocher P; Hillion D; Nochy D; Tennenbaum R; Vitte RL; Eugène C
Gastroenterol Clin Biol; 2002 Apr; 26(4):412-4. PubMed ID: 12070416
[TBL] [Abstract][Full Text] [Related]
39. Ouabain-containing Euro-Collins solution prevents acute tubular necrosis following kidney preservation.
Kumada N; Kim T; Ohyama A; Tujino T; Iwai Y; Itoh T; Sugimura K; Nakatani T; Yamamoto K; Kisimoto T
Transplant Proc; 1994 Apr; 26(2):935. PubMed ID: 8171708
[No Abstract] [Full Text] [Related]
40. Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure.
Megyesi J; Safirstein RL; Price PM
J Clin Invest; 1998 Feb; 101(4):777-82. PubMed ID: 9466972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
